DCM
ACRS icon

DAFNA Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

DAFNA Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,000
Closed -$1.76M – 81
2021
Q2 		$1.76M Buy
+100,000
New +$2.27M 0.37% 53

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

DAFNA Capital Management's ACRS Position: Q3 2021 in Review

DAFNA Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 100,000 shares — an estimated $1.76M sold.

DAFNA Capital Management first reported a position in ACRS in Q2 2021 and held it in 1 quarter. The position peaked at $1.76M in Q2 2021. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

  • DAFNA Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 100,000 Aclaris Therapeutics shares in Q3 2021, an estimated $1.76M.
  • DAFNA Capital Management first reported a position in Aclaris Therapeutics in Q2 2021 and held it in 1 quarter.
  • DAFNA Capital Management's Aclaris Therapeutics position peaked at $1.76M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.